Brought to you by 
Celgene buys Juno for $9bn
Jan 2018
Executive Summary
Confirming rumors that began swirling a week prior, Celgene Corp. announced that it signed a definitive agreement to acquire the remaining 90.3% of cellular immunotherapies developer Juno Therapeutics Inc. that it didn’t already own for $87 per share or roughly $9bn. The share price represents an 80% premium to Juno’s trading average for the ten days prior to the January 17 media speculation.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Includes Contract
- Intra-Biotech Deal
- Partial Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com